{"filings":[{"id":844276,"accession_number":"0001636422-26-000082","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2026-06-04T13:10:13+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Health Catalyst sells Vitalware to Med-Metrix for $147M; plans to repay term loan","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale price of $147M in cash, subject to customary adjustments; expected close in Q3 2026.","Net proceeds plus cash on hand to repay ~$160M senior secured term loan, including prepayment premiums.","Vitalware generated ~$37M in FY 2025 revenue; transaction sharpens focus on AI and core technology.","Closing conditions include HSR clearance and ≥80% of Vitalware employees accepting job offers from buyer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13092,"accession_number":"0001636422-26-000064","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2026-05-11T20:10:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q1 revenue falls 11% YoY; net loss widens to $111M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $70.8M vs $79.4M in Q1 2025; gross margin improved to 39% from 36%.","Net loss of $111.0M, a 368% increase year-over-year from $23.7M loss in prior-year period.","CEO Ben Albert says Q1 results exceeded expectations on revenue and adjusted EBITDA.","Company announces strategic reset to focus on highest-conviction technology opportunities.","Ticker: HCAT; Nasdaq-listed."],"consensus_eps_estimate":0.0175,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":70756000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94277,"accession_number":"0001636422-26-000051","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Health Catalyst appoints Aetna President Steve Nelson to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Nelson, EVP and President of Aetna (CVS Health), appointed to Health Catalyst board effective May 1, 2026.","Nelson fills a newly created board seat, expanding board from six to seven directors.","Appointment follows recent naming of Ben Albert as CEO and Justin Spencer as Chairman.","Board size will revert to six after the 2026 annual meeting as Matthew Kolb is not standing for re-election.","Nelson brings experience as former CEO of ChenMed, Duly Health and Care, and UnitedHealthcare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94276,"accession_number":"0001636422-26-000045","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Health Catalyst cuts ~9% workforce, eliminates CPO role as part of Project Nexus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized workforce reduction of ~9% (approx. 100 additional open headcount eliminated) on April 24, 2026.","Chief People Officer Linda Llewelyn will cease role June 1, 2026; will serve as senior advisor through Sept 1, 2026.","Workforce reduction is part of Project Nexus, a strategic initiative to simplify structure and align resources.","Company expects separation agreement with Llewelyn under Executive Severance Plan in exchange for release of claims.","Further details on impact to be provided in upcoming Form 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94275,"accession_number":"0001636422-26-000042","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Daniel Burton retires, becomes strategic advisor; forfeits unvested equity","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Burton retired as CEO Feb 12, 2026; Board resignation Feb 17, 2026.","Transition agreement effective March 31, 2026: serves as strategic advisor through Dec 31, 2026.","Monthly salary of $10,000 starting March 1, 2026; first three months' $30,000 paid in March.","All unvested RSUs and PRSUs forfeited as of March 3, 2026.","Executive signed general release of claims; subject to non-disparagement and confidentiality obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106510,"accession_number":"0001636422-26-000031","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst reports Q4 revenue down 6% YoY; net loss widens to $91M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $311.1M, up 1% YoY; Q4 revenue $74.7M, down 6% YoY.","Q4 net loss $91.0M vs $20.7M in Q4 2024; full-year net loss $178.0M vs $69.5M.","Adjusted EBITDA for full-year 2025 was $41.4M.","CEO Ben Albert cited opportunities and areas for improvement; focused on long-term success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106509,"accession_number":"0001636422-26-000015","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Health Catalyst appoints Ben Albert as CEO, accelerates CEO succession; board reduced to 5","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ben Albert appointed CEO and director effective Feb 12, 2026; Dan Burton steps down as CEO and from board.","Albert's compensation: $600k salary, 100% bonus target, 465k RSUs + 465k PRSUs.","Director resignations: Smith, Gallagher (Feb 17), Kane (Apr 1); board shrinks from 9 directors to 5.","Justin Spencer named chair of board; Matt Arens chairs nominating committee.","Albert previously COO since Sep 2025; prior CEO of Upfront Healthcare acquired Jan 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106508,"accession_number":"0001636422-26-000010","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Health Catalyst CCO Kevin Freeman to Depart, Remain as Senior Advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Freeman will cease serving as Chief Commercial Officer on February 1, 2026.","Company expects to enter a separation agreement and independent contractor agreement for senior advisor role starting February 2, 2026.","Separation benefits under Executive Severance Plan as summarized in May 2025 proxy statement.","Transition intended to enable smooth handover of commercial responsibilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106507,"accession_number":"0001636422-26-000006","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst releases preliminary unaudited 2025 results; details not provided in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Preliminary unaudited estimated 2025 financial and operational results published on Jan 12, 2026.","Exhibit 99.1 referenced but its contents were not included in the provided text; specific figures unknown.","Results are subject to change upon completion of annual audit procedures.","Forward-looking commentary was also provided but not detailed in the filing excerpt."],"consensus_eps_estimate":0.0928,"consensus_eps_actual":-2.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":311136000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122850,"accession_number":"0001636422-25-000156","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Health Catalyst appoints largest shareholder's CEO Matt Arens to board; Kolb not re-elected","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matt Arens, CEO/Founder of First Light (13.9M shares, ~19% ownership), appointed to Board effective Dec 1, 2025.","Board expanded from 8 to 9 directors; Arens fills new seat as Class I director until 2026 annual meeting.","Arens waives director compensation except expense reimbursement; enters voting/confidentiality agreement with First Light.","Director Matthew Kolb will not stand for re-election at 2026 annual meeting; no disagreement cited.","Board will reduce from 9 to 8 directors effective just before the 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122849,"accession_number":"0001636422-25-000143","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q3 revenue flat at $76.3M; net loss widens 51% to $22.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $76.3M, flat YoY; gross margin 39%, up from 36%.","Net loss $22.2M, widened 51% from $14.7M in Q3 2024.","Adjusted EBITDA $12.0M; results beat quarterly guidance on both revenue and EBITDA.","FY 2025 guidance reaffirmed."],"consensus_eps_estimate":0.0604,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":236457000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139554,"accession_number":"0001636422-25-000133","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Health Catalyst appoints Ben Albert as President and COO; Dan LeSueur transitions to advisory role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ben Albert appointed President and COO effective Sept 16, 2025; previously CEO of Upfront acquired by Health Catalyst in Jan 2025.","Albert's base salary $475,000, target bonus 75% of salary; receives 467,000 RSUs and 233,000 PRSUs tied to performance metrics.","Dan LeSueur ceases as COO on Sept 15, 2025; transitions to part-time advisory role. No disagreement.","CEO Dan Burton's previously announced retirement effective June 2026 remains; Board continues CEO search."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139553,"accession_number":"0001636422-25-000108","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Health Catalyst Q2 revenue $80.7M (+6% YoY), EBITDA $9.3M beat; CEO to retire June 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $80.7M (+6% YoY); Adjusted EBITDA $9.3M; both beat Q2 guidance.","Net loss widened 203% to $41.0M from $13.5M in prior year.","CEO Dan Burton to retire effective June 30, 2026; will remain on Board; CEO search initiated.","Board expanded to 8 directors; Justin Spencer (CFO Eko Health) appointed effective Sep 1, 2025."],"consensus_eps_estimate":0.0346,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":160134000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139552,"accession_number":"0001636422-25-000096","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Health Catalyst annual meeting results: all four proposals approved by stockholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Duncan Gallagher and Jill Hoggard Green as Class III directors for three-year terms.","Ratification of Ernst & Young as independent auditor for FY2025: 53,070,196 for, 26,656 against.","Advisory say-on-pay proposal approved with 45,000,705 votes for, 768,325 against.","Advisory vote to declassify Board of Directors approved with 46,174,256 votes for, 345,811 against.","Total shares present or by proxy: 53,125,841 out of 69,601,233 entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157124,"accession_number":"0001636422-25-000063","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q1 revenue $79.4M beats guidance; adds 10 net new Platform Clients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $79.4M, up 6% YoY; Adjusted EBITDA $6.3M, both above quarterly guidance.","Net loss widened to $23.7M from $20.6M YoY; gross margin fell to 36% from 39%.","Added 10 net new Platform Clients in Q1 2025; reaffirms target of 40 new clients for full year.","CEO cites strong start to year, with Q1 typically a quieter bookings quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":79413000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175484,"accession_number":"0001636422-25-000023","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01","5.02"],"status":"ready","headline":"Health Catalyst Q4 revenue $79.6M (+6% YoY); raises 2025 Adjusted EBITDA target to $41M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $79.6M (+6% YoY); full-year revenue $306.6M (+4% YoY).","Net loss improved to $20.7M in Q4 ($30.3M prior year); full-year net loss $69.5M vs $118.1M.","Technology segment Q4 revenue $52M (+10% YoY); full-year Tech revenue $195M.","2025 Adjusted EBITDA target raised to approximately $41M, up $2M from prior outlook.","Director Anita Pramoda resigns effective March 1; Dr. Jill Hoggard Green joined Board Dec 1. Also promotions: Chief AI Officer and leadership team appointments."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":306584000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175483,"accession_number":"0001636422-25-000010","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Health Catalyst acquires Upfront Healthcare for ~$86M net; reports preliminary Q4 & FY2024 results and 2025 guidance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront acquisition: ~$86M net consideration (cash + ~5.75M shares) plus up to ~$33.4M earn-out; expected Q1 2025 close.","Preliminary Q4 2024 revenue $78.75-79.75M (+6% YoY), Adj. EBITDA $7.9M (10% margin).","Full-year 2024 revenue $305.7-306.7M (+3%), Adj. EBITDA $26.1M (+137%, 9% margin).","2025 guidance: revenue ~$335M (+10%), Adj. EBITDA ~$39M (+49%, 12% margin).","Net new platform clients 21 in 2024 (+91%); 2025 target ~40 (+90%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192441,"accession_number":"0001636422-24-000148","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Health Catalyst Q3 revenue $76.4M, Adj. EBITDA $7.3M; acquires Intraprise for $43M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 total revenue $76.4M, net loss $14.7M, Adjusted EBITDA $7.3M (above guidance midpoint of $6-8M).","FY 2024 Adjusted EBITDA guidance raised to $25-27M (from $24-26M); revenue guidance unchanged at $305-311M.","Acquired Intraprise Health for $43M (cash and ~2.2M shares at $8.18); expected close by end of 2024, immaterial near-term financial impact.","Appointed Dr. Jill Hoggard Green to board effective Dec 1, 2024; she is former CEO of The Queens Health System, a client."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":226978000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208909,"accession_number":"0001636422-24-000116","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst beats Q2 2024 guidance: revenue $75.9M, Adj. EBITDA $7.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $75.9M (+4% YoY); net loss $13.5M vs $32.6M loss in Q2 2023.","Adjusted EBITDA $7.5M, exceeding guidance midpoint of $6.0M.","Reiterates FY 2024 revenue $304-312M and Adj. EBITDA $24-26M; Q3 rev guidance $74.5-77.5M.","Signed more net new platform subscription clients in 1H 2024 than all of 2023; targeting low-20s for FY.","Announced $225M credit facility with Silver Point Finance and acquisitions of Carevive and Lumeon."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":150625000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208908,"accession_number":"0001636422-24-000107","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Health Catalyst enters $225M term loan with Silver Point; $125M drawn to refinance 2025 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial term loan of $125M funded July 16, 2024; proceeds to refinance convertible notes due 2025 and for working capital.","Delayed draw facility of $100M (up to $40M within 6 months, $60M within 18 months) for acquisitions.","Interest: SOFR loans at Term SOFR (floor 1%) + 6.50%; base rate loans at ABR (floor 2%) + 5.50%.","Maturity July 16, 2029; quarterly amortization of 0.25% of original principal; prepayment premiums up to 3%+make-whole.","Covenants include minimum liquidity and leverage ratios; collateral secured by substantially all assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226716,"accession_number":"0001636422-24-000097","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Health Catalyst annual meeting elects directors, ratifies auditor, approves executive pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class II directors Daniel Burton, John Kane, Julie Larson-Green re-elected each with >30M votes.","Ratification of Ernst & Young as independent auditor for FY2024: 49,068,137 for, 106,662 against.","Advisory say-on-pay vote approved: 42,599,851 for, 597,262 against, 12,669 abstentions.","Total shares present or by proxy: 49,177,309 out of 59,033,536 entitled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226715,"accession_number":"0001636422-24-000072","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q1 revenue $74.7M, Adj EBITDA $3.4M; beats guidance mid-point","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $74.7M (up 1% YoY), net loss $20.6M (improved 38% from $33.2M loss).","Adjusted EBITDA $3.4M above Q1 guidance range of $2M-$4M.","Reiterates FY2024 revenue guidance $304M-$312M and Adj EBITDA $24M-$26M.","Q2 2024 guidance: revenue $73.5M-$76.5M, Adj EBITDA $5M-$7M.","New platform branded Health Catalyst Ignite; expansion with Saudi German Health announced."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":74723000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245677,"accession_number":"0001636422-24-000015","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01","5.02"],"status":"ready","headline":"Health Catalyst Q4 rev $75.1M (+9% YoY), FY rev $295.9M; CFO Hunt resigns, Alger named CFO; guides 2024 rev $304-312M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $75.1M, up 9% YoY; net loss $30.3M; adjusted EBITDA $1.4M (in line with guidance midpoint).","FY2023 total revenue $295.9M, beat guidance midpoint; net loss $118.1M; adjusted EBITDA $11.0M (in line with guidance).","2024 guidance: revenue $304-312M; adjusted EBITDA $24-26M (~125%+ YoY growth at midpoint).","CFO Bryan Hunt resigns effective March 1, replaced by CAO Jason Alger; Dan LeSueur appointed COO effective same date.","Director Mark Templeton resigns effective March 1; 13,405 RSUs accelerated vesting; no disagreement cited."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":295938000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245676,"accession_number":"0001636422-24-000004","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Health Catalyst reports preliminary 2023 revenue and EBITDA above guidance; guides 2024 EBITDA ~$25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2023 total revenue above guidance midpoint (range $70.1M–$75.1M); Adjusted EBITDA at or above midpoint ($0.3M–$2.3M).","Preliminary FY 2023 total revenue above guidance midpoint ($291M–$296M); Adjusted EBITDA at or above midpoint ($10M–$12M).","2023 Dollar-Based Retention Rate approx 100%, below forecast 102%-110%, due to timing delays on large TEMS expansions.","Anticipates 2024 Adjusted EBITDA of ~$25M and 2025 Adjusted EBITDA margin target of 10% or greater.","Expects improvement in 2024 net new DOS Subscription Client bookings and retention rate relative to 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263146,"accession_number":"0001636422-23-000129","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst beats Q3 guidance; raises FY2023 revenue outlook; Adj. EBITDA positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $73.8M (+8% YoY), above guidance midpoint; net loss $22.0M vs $45.7M loss in Q3 2022.","Adjusted EBITDA $2.0M (improvement from -$4.6M YoY), also above guidance midpoint of $1.25M.","Raised FY2023 revenue guidance to $291M-$296M from $290.5M-$295.5M; reiterated Adj. EBITDA $10M-$12M.","New DOS client: Accountable Health Partners (~400k patients); Q4 expected to be a large bookings quarter.","Mid-term targets: revenue reacceleration in 2024, 10% Adj. EBITDA margin in 2025, long-term 20%+ growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":220854000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263145,"accession_number":"0001636422-23-000124","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst beats Q3 rev midpoint; raises FY rev guidance; Adj. EBITDA positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $73.8M (+8% YoY); tech revenue $46.0M (+4%), pro services $27.8M (+14%).","Net loss $22.0M vs $45.7M loss YoY (improved 52%); loss from ops $24.6M vs $45.7M.","Adjusted EBITDA $2.0M vs ($4.6M) loss a year ago; Q3 beat midpoint on both rev and EBITDA.","Raised FY2023 revenue guidance range; reiterated FY2023 Adjusted EBITDA guidance.","Full Q3 results and conference call rescheduled to November 2, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":220854000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280359,"accession_number":"0001636422-23-000095","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q2 revenue $73.2M beats midpoint; raises FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $73.2M (+4% YoY) vs guidance midpoint of $72.3M.","Adjusted EBITDA $3.5M vs guidance midpoint of $2.75M; margin ~5% (+200 bps YoY).","Two large TEMS contracts signed: ~$50M and ~$60M, each with existing health system clients.","FY2023 revenue guidance raised to $290.5M–$295.5M; Adjusted EBITDA raised to $10.0M–$12.0M.","Net loss improved to $32.6M from $33.4M YoY; dollar-based retention reiterated at 102%–110%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":147081000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298888,"accession_number":"0001636422-23-000086","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Health Catalyst stockholders elect directors, ratify auditor, approve exec compensation at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Anita V. Pramoda and S. Dawn Smith as Class I directors for three-year terms expiring 2026.","Ratified Ernst & Young as independent auditor for FY2023 with 47,292,765 votes for, 108,336 against.","Advisory vote on named executive officer compensation approved with 40,672,307 for, 1,663,691 against.","Total shares outstanding: 56,259,662; 46,806,678 present at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298887,"accession_number":"0001636422-23-000056","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q1 revenue up 8% to $73.9M, Adj. EBITDA $4.2M beats guidance; expands Allina Health pact","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $73.9M (+8% YoY); Technology revenue $47.2M (+12%), Professional services $26.7M (+3%).","GAAP net loss $33.2M (widened 48% YoY); Adjusted EBITDA $4.2M (up 521%, above guidance midpoint).","Expanded tech-enabled managed services partnership with Allina Health; recurring revenue now ~$11M/year.","Adjusted Technology Gross Margin 70% (flat); Adjusted Professional Services Gross Margin fell to 20% from 29%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":73868000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319074,"accession_number":"0001636422-23-000041","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Health Catalyst appoints COO/CPO and new General Counsel; GC Orenstein to step down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anne Marie Bickmore, current CPO, becomes COO and CPO effective April 3, 2023.","Daniel Orenstein resigns as General Counsel and Corporate Secretary effective April 30, 2023, to pursue other opportunities.","Benjamin Landry, Assistant General Counsel, promoted to General Counsel and Corporate Secretary effective May 1, 2023.","Orenstein to remain as Senior Advisor under independent contractor agreement for transition.","No disagreement or conflict cited for Orenstein's departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319073,"accession_number":"0001636422-23-000038","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Health Catalyst says SVB deposits are under 1% of cash and investments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposits with Silicon Valley Bank represent less than 1% of total cash, cash equivalents, and short-term investments as of March 10, 2023.","Company acknowledges SVB closure and FDIC receivership but reports minimal exposure.","No material financial impact expected from SVB failure based on current deposit levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319072,"accession_number":"0001636422-23-000034","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Health Catalyst appoints Carle Health COO Matthew Kolb to board; Carle becomes shareholder","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew Kolb, EVP & COO of Carle Health, appointed to board effective July 1, 2023, filling a newly created seat.","Carle Health purchased HCAT common stock on open market, becoming a meaningful shareholder.","Carle expanded client relationship in Dec 2022 with a five-year contract for tech-enabled managed services and all-access subscription.","Carle paid ~$5.5M in 2022; 2023 payments expected to slightly exceed 5% of HCAT's projected revenue.","Kolb will not receive director compensation beyond expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319071,"accession_number":"0001636422-23-000026","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q4 revenue $69.2M (+7% YoY); Adjusted EBITDA loss narrows; board adds Matthew Kolb","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $69.2M (+7% YoY); full-year revenue $276.2M (+14% YoY).","GAAP net loss Q4 $35.8M vs $49.0M loss a year ago; full-year net loss $137.4M vs $153.2M.","Adjusted EBITDA Q4 -$0.6M (improved 90% from -$6.3M); full-year -$2.5M (improved 78% from -$11.2M).","Matthew Kolb (EVP/COO Carle Health) to join board effective July 1, 2023; Carle Health made open-market stock purchase.","CEO Dan Burton purchased shares on open market, estimates he is among top 20 shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":276236000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319070,"accession_number":"0001636422-23-000011","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HCAT files 8-K for JPM conference presentation; specific content unavailable","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Health Catalyst plans to present at J.P. Morgan Healthcare Conference on January 10, 2023.","Presentation attached as Exhibit 99.1 includes forward-looking statements and business overview.","No quantitative financial data or guidance changes evident in the available filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319069,"accession_number":"0001636422-23-000007","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Health Catalyst COO Paul Horstmeier to step down March 31 for 3-year church mission","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Paul Horstmeier will step down effective March 31, 2023, called to lead Puerto Rico San Juan Mission for 3 years.","Horstmeier will become Senior Advisor to ensure smooth transition of responsibilities to other senior leaders.","Departure is not due to any disagreement; it is a personal religious calling.","This is the second time a Health Catalyst senior leader has taken a 3-year mission; previous was co-founder Steve Barlow (2017-2020).","Horstmeier has been with Health Catalyst for 11.5 years; CEO Dan Burton praised his contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319068,"accession_number":"0001636422-23-000005","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K/A","filed_at":"2023-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Health Catalyst finalizes separation with ex-President Nelli; $258,740 cash, 72K RSUs accelerated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["J. Patrick Nelli separated from Health Catalyst effective Dec 31, 2022; severance includes $258,740 lump sum (9 months salary + COBRA).","Accelerated vesting of 72,096 restricted stock units upon separation.","One-year extension of expiration date for certain previously vested stock options.","Nelli had transitioned from President to Senior Advisor as of Sept 30, 2022, before the separation.","Separation agreement includes general release of claims and restrictive covenant compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337299,"accession_number":"0001636422-22-000050","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q3 revenue $68.4M (+11% YoY), beats guidance; raises FY2022 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $68.4M (+11% YoY); technology revenue $43.9M (+15%), professional services $24.4M (+4%).","GAAP net loss $45.7M; adjusted EBITDA loss $4.6M, improving 21% YoY.","Raised full-year 2022 revenue and adjusted EBITDA guidance; dollar-based retention now expected 97-101%.","CEO Dan Burton highlighted strong pipeline and cost reduction efforts ahead of schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":207074000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354666,"accession_number":"0001636422-22-000044","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Health Catalyst appoints new CRO as Chief Growth Officer; President Nelli transitions to Senior Advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Three new leadership appointments: Kevin Freeman as Chief Growth Officer, Tarah Neujahr Bryan as CMO, Dave Ross as CTO, effective Sept 7, 2022.","President Patrick Nelli transitions to Senior Advisor effective Sept 30, 2022; departure is mutual, not due to disagreement.","CTO Bryan Hinton to complete tenure on Sept 30, 2022.","New growth leadership aligns with strategic focus on deepening client relationships and adding new clients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354665,"accession_number":"0001636422-22-000039","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Health Catalyst approves $40M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $40 million in common stock repurchases effective immediately.","Repurchases may occur in open market or privately, with timing at management's discretion.","Company held $403.3 million in cash and short-term investments as of June 30, 2022.","Program can be modified, suspended, or terminated at any time; no obligation to repurchase any specific amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354664,"accession_number":"0001636422-22-000038","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q2 revenue up 18% to $70.6M; lowers full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $70.6M, up 18% YoY; Technology revenue $45.4M (+28%), Professional services $25.2M (+5%).","GAAP net loss $33.4M vs $35.8M loss a year ago; Adjusted EBITDA $2.0M, up 20%.","Adjusted Technology Gross Margin 70%, Adjusted Professional Services Gross Margin 27%.","Revising down full-year 2022 revenue and Adjusted EBITDA outlook citing challenging end-market environment."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":138720000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372669,"accession_number":"0001636422-22-000027","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Health Catalyst shareholders reject advisory vote on executive compensation at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Say-on-pay proposal received 20,019,370 for, 23,100,748 against, 46,068 abstain, 3,010,476 broker non-votes.","Both Class III director nominees elected: Duncan Gallagher (28,400,049 for, 14,766,137 withheld) and Mark B. Templeton (33,605,452 for, 9,560,734 withheld).","Ratification of Ernst & Young as auditor for FY2022 passed: 45,758,062 for, 378,823 against, 39,777 abstain.","Total shares present at meeting: 46,176,662 of 53,937,142 entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372668,"accession_number":"0001636422-22-000023","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q1 revenue $68.1M (+22% YoY), positive Adjusted EBITDA $671K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $68.1M, +22% YoY; technology revenue $42.2M (+25%), professional services $25.9M (+17%).","Adjusted EBITDA turned positive to $0.7M from -$0.8M in Q1 2021; net loss narrowed 21% to $22.5M.","Adjusted Technology Gross Margin improved to 70% (from 69%); Professional Services margin slipped to 29% (from 31%).","CEO says Q1 exceeded midpoint of guidance for both revenue and Adjusted EBITDA; achieved Adjusted EBITDA breakeven milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":68087000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391491,"accession_number":"0001636422-22-000010","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q4 revenue $64.7M (+21% YoY), beats guidance midpoint; FY revenue $241.9M (+28%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue of $64.7M (+21% YoY); full-year revenue of $241.9M (+28% YoY).","Q4 GAAP net loss $49.0M vs $43.0M a year ago; full-year net loss $153.2M vs $115.0M.","Q4 Adjusted EBITDA -$6.3M vs -$4.7M YoY; full-year -$11.2M, improving 47% from -$21.3M.","Technology revenue Q4 $40.1M (+24% YoY); full year $147.7M (+34%).","CEO confirmed Q4 revenue and Adjusted EBITDA exceeded mid-point of prior guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":241926000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409689,"accession_number":"0001636422-21-000075","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q3 revenue beats guidance, adjusted EBITDA loss improves 10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $61.7 million (+31% YoY); technology revenue $38.3 million (+37%) and professional services $23.5 million (+22%).","GAAP net loss $40 million (vs $27.3 million loss in Q3 2020); operating loss $42.2 million (vs $23.5 million).","Adjusted EBITDA loss $(5.8) million improved 10% from $(6.4) million loss in prior-year quarter.","Adjusted technology gross margin 70% (up from 68%); total adjusted gross margin flat at 51%.","CEO Dan Burton noted strong Q3 performance, exceeding mid-point of guidance for both revenue and adjusted EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":177210000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428596,"accession_number":"0001628280-21-016975","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2021-08-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Health Catalyst closes public offering of 4.25M shares, netting ~$213M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of 4,245,283 shares of common stock closed on August 13, 2021.","Net proceeds of approximately $213.1 million after underwriting discounts and expenses.","Underwriters included J.P. Morgan, Goldman Sachs & Co. LLC, and Evercore Group L.L.C.","Company agreed to a 60-day lock-up on further sales of common stock, subject to exceptions.","Offering made under shelf registration statement (File No. 333-258625) filed August 9, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428595,"accession_number":"0001636422-21-000067","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Health Catalyst Q2 revenue up 38% to $59.6M; first positive adjusted EBITDA of $1.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $59.6M (+38% YoY); technology revenue $35.5M (+39%).","Net loss $35.8M (loss from operations $32.3M); adjusted EBITDA positive $1.7M (first-time positive).","Adjusted technology gross margin 68%; adjusted professional services gross margin 34% vs 21% YoY.","Closed acquisition of Twistle on July 1, 2021 to bolster Population Health analytics.","CEO exceeded mid-point guidance for both revenue and adjusted EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":115473000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428594,"accession_number":"0001636422-21-000059","cik":1636422,"company_name":"Health Catalyst, Inc.","ticker":"HCAT","form_type":"8-K","filed_at":"2021-08-02T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Health Catalyst amends bylaws to mandate federal court for Securities Act claims","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved bylaw amendment effective July 29, 2021, designating federal district courts as exclusive forum for Securities Act of 1933 litigation.","Any person acquiring shares is deemed to have notice and consented to the exclusive forum provision.","Amendment aims to reduce potential expenses from defending actions in multiple jurisdictions simultaneously."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":101604274.32692309,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}